Dr Reddy's launches anti-cancer injection in US

The market for Docetaxel in the US is worth $218 million

Dr Reddy's Laboratories has launched Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a generic version of Taxotere (docetaxel injection) in the US market.

Dr Reddy's Abbreviated New Drug Application (ANDA) is approved by the United States Food & Drug Administration (USFDA), DRL said in a statement today.

Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Its brand and generic versions have US sales of approximately $218 million MAT for the most recent 12 months ending in September, the drug maker said quoting IMS Health data.

Dr Reddy's Docetaxel injection USP 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution, it added.